Skip to Main Content
Our Commitment to Diversity

Exchanges Adopt Generic Listing Standards for Actively Managed ETFs

Date: 18 November 2016
Exchange-Traded Funds Alert
By: Stacy L. Fuller, Aaron E. Ellias, Timothy A. Bekkers

Earlier this year, the Securities and Exchange Commission (“SEC”) approved new rules proposed by Bats BZX Exchange, Inc. (“Bats”) and NYSE Arca, Inc. (“Arca”) that establish generic listing standards (“Active Generics”) for qualifying actively managed exchange-traded funds (“ETFs”).[1]  The Active Generics dramatically streamline and simplify the Exchanges’ listing process for firms looking to bring actively managed ETFs to market.  Actively managed ETFs may list under the Active Generics if they satisfy the criteria described below.[2]

Click here to read the full alert.

[1] Securities Exchange Act Rel. No. 24-78005 (June 7, 2016) (SR-BATS-2015-100) (“Bats Proposal”); Securities Exchange Act Rel. No. 34-78016 (June 8, 2016) (SR-NYSEArca-2015-110) (“Arca Proposal”).  On September 23, 2016, the SEC approved similar rules proposed by NASDAQ Stock Market, LLC ( together with Bats and Arca, the “Exchanges”). Securities Exchange Act. Rel. No. Release No. 34-78616 (Aug. 18, 2016) (SR-NASDAQ-2016-104).

[2] Actively managed ETFs that already list may continue to do so under the rules crafted during their Rule 19b-4 listing process.  New actively managed ETFs that do not satisfy the Active Generics may still seek to list under the Rule 19b-4 listing process.

This publication/newsletter is for informational purposes and does not contain or convey legal advice. The information herein should not be used or relied upon in regard to any particular facts or circumstances without first consulting a lawyer. Any views expressed herein are those of the author(s) and not necessarily those of the law firm's clients.

Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel